HIV/AIDS Topics Coverage of the 2015 National HIV Prevention Conference
- Details
- Category: HIV Prevention
- Published on Thursday, 17 December 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2015 National HIV Prevention Coference, (NHPC 2015), December 6-9 in Atlanta.
Conference highlights include HIV pre-exposure prophylaxis (PrEP), antiretroviral treatment as prevention, syringe exchange, and addressing disparities in HIV incidence and outcomes.
7/22/15
NHPC 2015: Evidence for PrEP Efficacy Grows, but Implementation Presents Challenges
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 16 December 2015 00:00
- Written by Liz Highleyman
Pre-exposure prophylaxis (PrEP) was a major topic at the 2015 National HIV Prevention Conference(NHPC) last week in Atlanta. A growing body of evidence continues to confirm that Truvada PrEP is highly effective for preventing HIV if taken regularly, both in clinical trials and in real-world clinical use. Yet uptake has been uneven, and researchers and front-line health workers are learning about barriers to PrEP implementation and scale-up for diverse population groups.
Trials Offer Evidence-based Blueprint for HIV Treatment and Prevention
- Details
- Category: HIV Treatment
- Published on Tuesday, 15 December 2015 00:00
- Written by HIVandHepatitis.com
A trio of major clinical trials -- SMART, START, and HPTN 052 -- provide definitive evidence supporting prompt antiretroviral treatment for all people diagnosed with HIV, both to improve their own health and to reduce the risk of transmission to others, according to a recent commentary published in the December 3 edition of the New England Journal of Medicine. Further, results from the IPERGAY study, published in the same issue, add to the growing body of evidence supporting pre-exposure prophylaxis (PrEP) for HIV prevention.
NHPC 2015: U.S. Syringe Funding Ban Impedes HIV and Hepatitis C Prevention
- Details
- Category: Injection Drug Use
- Published on Tuesday, 15 December 2015 00:00
- Written by Liz Highleyman
Providing sterile syringes is a proven effective method for preventing HIV and hepatitis C virus (HCV) infections among people who inject drugs, yet the U.S. government continues to prohibit use of federal funds for this purpose, presenters said at the 2015 National HIV Prevention Conference (NHPC) last week in Atlanta. A federal budget bill now under consideration could lift the funding ban on syringe exchange programs.
Drug Resistance Acquired During HIV PrEP Rapidly Disappears After Discontinuation
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 15 December 2015 00:00
- Written by Michael Carter
Drug resistance acquired in rare cases of HIV infection occurring while on pre-exposure prophylaxis (PrEP) rapidly disappears once the medication is discontinued, investigators with the Partners PrEP Study Teamreport in the January 2, 2016, edition of AIDS. Use of ultra-sensitive tests performed 6 months after seroconversion and discontinuation of Truvada for PrEP failed to find any remaining resistant virus.
Web Design and Development by